How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Transgenic mice expressing human toll-like receptor 4 (hTLR4)

Organization name

Max-Planck-Innovation GmbH

Profile

Background

TLR4 is the signaling receptor responsible for recognizing lipopolysaccharide (LPS), a major marker for gram-negative pathogens and a highly potent activator of the innate immune response. After activation of TLR4 in a variety of different cells like macrophages, granulocytes and dendritic cells, LPS triggers the release of a large spectrum of inflammatory mediators leading to an immune response. If inappropriately strong, this response might cumulate in endotoxin shock and death. Furthermore, by using transgenic mice expressing the human variant of TLR4, it has been shown that hTLR4 (but not mTLR4) is a direct target for nickel (Ni2+) and as a consequence plays a crucial role in the development of contact allergy. Mice expressing the human variant of TLR4 therefore provide an excellent animal model to be used in preclinical studies for the development of anti-inflammatory drugs based on interference with TLR4-mediated signaling.

Technology

Scientists from the Max-Plack-Institute for Immunobiology in Freiburg developed transgenic mice that express human toll-like receptor 4 (hTLR4) on a mTlr4-/- background. Mice were derived by pronuclear injection of fertilized eggs from the C57BL/10ScCr (Cr) mouse strain. These mice bear a natural deletion of the Tlr4 gene and are known to have an additional IL-12Rβ2 defect that was removed by backcrossing to the mTlr4-/-, Cr-progenitor strain C57BL/10ScN. Following strains that carry a hTlr4-transgene are available for licensing:

hTLR4tr/trmTLR40/0IL-12Rβ2n/n

and

hTLR4tr/trmTLR40/0IL-12Rβ2d/d

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries